Byron S. Kalogerou - McDermott Will & Emery


Byron S. Kalogerou is the founder of the Firm’s Life Science Industry Group and the senior partner in the Boston Corporate Practice. He helps clients execute on their growth strategies by guiding them through complex domestic and cross-border mergers and acquisitions and joint ventures and alliances. He also assists early stage life science companies in their capital raising efforts. Byron has extensive industry background in the life science, industrial and manufacturing sectors. He also acts as outside general counsel to a number of companies.

Show More


  • Advised Merck KGaA, Darmstadt, Germany, a leading science and technology company, in the entry of a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO) that specializes in complex injectable formulations, for US $780 million
  • Represented Xcovery, Inc. an oncology focused bio-pharmaceutical company and subsidiary of China-based Betta Pharmaceuticals (300558.SZ), in its acquisition of a majority and controlling stake in Meryx Inc., a clinical stage immune-oncology company developing TKI’s in a range of hematologic and solid malignancies, including lung cancer.
  • Advised Medline, Inc., a family-owned maker and distributor of medical devices and equipment, on the healthcare regulatory elements of the $30 billion leveraged buyout by a consortium of private equity firms, including Blackstone Group, Carlyle Group and Heller & Friedman

Show More


  • The Legal 500 US, Recommended, 2012-2018, 2022-2023
  • Chambers USA, 2022
  • Acritas Stars 2019-2020, listed among independently rated lawyers
  • LMG Life Sciences, Life Science Star 2016, 2018, 2019, 2020


  • American Bar Association, Committee on Mergers and Acquisitions, Co-Chair, Task Force on Legal Project Management


Vermont Law School, JD, 1986
Harvard Business School, Advanced Management Program Certificate, 2001
Dartmouth College, BA, 1983
Phillips Exeter Academy, 1979